DNA Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

$DNA RSI reset for more boom boom. Earnings will account for sales of autonomous lab at Pacific Northwest National. Everything gonna be alright.

$DNA Ginkgo’s latest earnings highlighted encouraging progress: revenue rose sequentially from $20 million to $28 million, while operating efficiency improved significantly. Adjusted EBITDA losses narrowed from $53 million to $22 million versus last year. The company ended September with $285 million in cash and securities. Its first autonomous laboratory sale to Novo marks an important commercial milestone. New pharmaceutical customers, government projects and AI training partnerships expand its opportunity. With 22 ADME customers signed during the quarter, Ginkgo is building tangible commercial momentum around laboratory automation, cloud services and biological data.

$DNA They have failed at every venture / promise given so far. Their current business model is based off of automated carts from an acquisition they made years ago. Don’t be fooled by headlines linking ginkgo to larger companies. It has happened plenty in the past and has yet to result in anything other than declining revenues YOY. To the newcomers…there is zero reason to trust management until they show meaningful revenue growth. Jason Kelly is the last person you’d want to trust with your money.

$DNA What would make it a good report: * Revenue above roughly $23 million, alongside stronger customer demand. * Lower cash burn and a longer funding runway. * Paid automation contracts that translate into revenue. * A more encouraging outlook for 2027.

$DNA well well well. not a bad week. up 4.4% while the QQQ was down 5.6% and XBI down 2.7%.

$DNA Very early here, but worth watching to see if they have FINALLY come up with a business model that is durable. Management flagged timing uncertainty in converting autonomous lab demand into reported revenue, with CEO Kelly stating customers often plan installs “6 to 12” months out and CFO Coen reiterating, “we’re not giving guidance on revenue” (CEO Kelly; CFO Coen). Final takeaway Management framed Q3 2026 as a proof point for Ginkgo’s autonomous lab pivot, pointing to a first “big pharma” autonomous lab build with Novo Nordisk, additional government-linked work (including “up to a $17.5 million award” with ARPA-H), and growing cloud lab adoption, while reiterating full-year 2026 cash burn guidance of $125 million to $150 million and emphasizing that hardware revenue is generally recognized “when the system is installed,” with recurring services and software revenue intended to build as deployments scale.

$DNA revenue down, losses up, didn’t watch the call yet but I bet there was another Waymo analogy! 😂

$DNA Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.64 up 55.86% YoY • Reported revenue of $27.71M down -28.66% YoY • Ginkgo Bioworks reaffirmed expected total cash burn of ($150)--$125M in 2026; quantified revenue, margin, and earnings guidance was not provided in this outlook update.

$DNA lottery ticket. Don’t know what to make of it here. Need a biochem PHD to provide product insight.

$DNA Super difficult to predict. No Man’s Land again. Something under $8 might be worth a flier. The technical analysis with this stock is like handling Mercury. Difficult.

$DNA high alert 🧨🧨 People saying going to moon this week. I say you’re nuts!!’ Yet very soon if you measure time same way. A solid catch. Keep fishing 🤙

$DNA openai visits south korea, in talk with biotech companies. ginkgo always had korea in mind , as a market or as a partner ....something is cooking

$DNA election drama may turn tides for ginkgo. all those aid taken away may come back along with other govt funding. maybe it's time for a milestone reveal, the datacenter slump will continue, so rotation to high beta and biotech might continue ....

$DNA this guy doesn’t know what he is talking about if you listen to him bue bye money

$DNA what did i tell you SELL all your positions you guys are getting scammed i am not bearish for no reason pls for the sake of your money sell this POS

$DNA absolutely lolx. And jason is good buds with john melo and doerr, so hes learning from the best. Lmao

$DNA the volume this time is multiple of daily avg whenever there is a run. this is not the short covering as earlier just before earnings. remember total shares are just around 60 to 70mn. no wonder jumps go more than 15 to 20% very quickly. physical ai is ready. including biotech in coins act was a push from Jason, and he won. this will rise much much faster now ...

$DNA OpenAI + Orchestra Bio: OpenAI announced its acquisition of Orchestra Bio on October 20, 2026. Orchestra develops AI agents that coordinate drug-development programs.  OpenAI + Ginkgo Bioworks: Ginkgo already works with OpenAI technology. In February 2026, Ginkgo announced that its autonomous laboratory, powered by GPT-5, achieved a 40% improvement over a scientific benchmark. 

$DNA Ginkgo Bioworks Holdings press release (DNA): Q3 GAAP EPS of -$0.64 beats by $0.22. Revenue of $27.7M (-5.7% Y/Y) beats by $6.19M. Full Year 2026 Outlook Ginkgo reaffirms expected total cash burn of ($150)-($125) million in 2026.

$DNA till november 5 stock is going to tank, and if you are hoping for good earnings from this company i am sorry for you